Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

419
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
419
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

669
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
669
Menopause01:28

Menopause

166
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
166
Spermatogenesis01:41

Spermatogenesis

102.5K
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
102.5K
Infertility in Males01:23

Infertility in Males

264
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
264
Signs of Puberty01:27

Signs of Puberty

353
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.

Nanomedicine (London, England)·2026
Same author

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026
Same author

Publisher Correction: Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.

Nature nanotechnology·2026
Same author

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).

Clinical genitourinary cancer·2026
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer.

Mark A Preston1, Agnes Hong2, Robert Dufour3

  • 1Brigham and Women's Hospital, Boston, MA, USA.

European Urology Open Science
|February 1, 2024
PubMed
Summary

Delayed testosterone recovery in prostate cancer patients after androgen deprivation therapy (ADT) is linked to increased risks of diabetes and depression. Monitoring testosterone levels post-ADT is crucial for managing long-term health in these patients.

Keywords:
Androgen deprivation therapyProstate cancerReal-world studyTestosterone recovery

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.4K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.7K

Related Experiment Videos

Last Updated: Jul 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.4K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.7K

Area of Science:

  • Oncology
  • Endocrinology
  • Health Services Research

Background:

  • Medical androgen deprivation therapy (ADT) is a cornerstone treatment for prostate cancer.
  • Delayed testosterone recovery (TR) after ADT discontinuation is a recognized clinical concern.
  • The long-term health implications of suboptimal TR remain incompletely understood.

Purpose of the Study:

  • To evaluate the clinical impact of delayed testosterone recovery (TR) following the discontinuation of medical androgen deprivation therapy (ADT) in prostate cancer patients.
  • To identify associations between TR status and the development of new-onset comorbidities.
  • To inform clinical practice regarding post-ADT monitoring.

Main Methods:

  • Retrospective, longitudinal analysis of adult males with prostate cancer using de-identified Electronic Health Record data (2010-2021).
  • Inclusion criteria: initiated and discontinued ADT, with at least one testosterone level test within 12 months post-discontinuation.
  • Cohorts: TR (>280 ng/dL testosterone within 12 months) vs. non-TR. Adjusted for baseline characteristics.

Main Results:

  • Of 1553 patients meeting criteria, 25% achieved TR and 75% did not.
  • The TR cohort demonstrated a significantly lower risk of new-onset diabetes (HR 0.47; 95% CI 0.27-0.79).
  • TR cohort trended towards lower risk of new-onset depression (HR 0.58; 95% CI 0.33-1.02) and higher likelihood of seeking treatment for sexual dysfunction (HR 1.33; 95% CI 0.99-1.78).

Conclusions:

  • Delayed testosterone recovery after ADT discontinuation is associated with increased risk of new-onset diabetes and potentially depression.
  • Monitoring testosterone levels post-ADT is essential for proactive management of comorbidities in prostate cancer patients.
  • These findings support optimizing clinical decision-making for patients undergoing ADT cessation.